View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
June 24, 2009

Last Moment Launch for Finasteride in France

Actavis has launched the prostate cancer drug Finasteride in France, only one day before the patent expired. The distribution of Finasteride Actavis has already been initiated after the launch by the company under its brand name, and at the same time by various Medis clients.

By cms admin

Actavis has launched the prostate cancer drug Finasteride in France, only one day before the patent expired.

The distribution of Finasteride Actavis has already been initiated after the launch by the company under its brand name, and at the same time by various Medis clients.

Finasteride is the generic equivalent of Merck’s Proscar and is used for the treatment of prostate cancer.

Finasteride Actavis is available in tablets of 5mg in France.

Finasteride Actavis was developed by Actavis in Iceland, and has already been launched by Actavis and its third-party clients in several European countries and in the US.

Actavis is an Iceland-based company focused on the development, manufacture and sale of generic pharmaceuticals.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology